Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 458-430-3 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 26/07/1996 to 19/03/1997
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 998
- Report date:
- 1998
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Version / remarks:
- Annex V (28 day study)
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Test material form:
- liquid
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Japan, Inc.
- Age at study initiation: Five weeks old.
- Weight at study initiation: Males: 146.8-167.0 g; Females: 118.4-142.6 g.
- Fasting period before study: None.
- Housing: Individually in hanging stainless steel cages with wire-mesh floor.
- Diet (e.g. ad libitum): Ad libitum.
- Water (e.g. ad libitum): Ad libitum.
- Acclimation period: Animals acclimatised but period not specified.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21-25.
- Humidity (%): 45-65.
- Air changes (per hr): 10-15.
- Photoperiod (hrs dark / hrs light): 12/12.
IN-LIFE DATES: From: To:
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- olive oil
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS: Test substance was accurately weighed and dissolved with olive oil to make a 10.0 w/v% solution, and the solution was prepared more than once per week. Dilutions were made from the 10% solution.
VEHICLE
- Justification for use and choice of vehicle (if other than water): No data.
- Concentration in vehicle: 0.08, 0.4, 2.0, 10%.
- Amount of vehicle (if gavage): Dependent on dose.
- Lot/batch no. (if required): No data.
- Purity: No data. - Analytical verification of doses or concentrations:
- no
- Duration of treatment / exposure:
- 28 days
- Frequency of treatment:
- Daily (7 days/week)
Doses / concentrations
- Remarks:
- Doses / Concentrations:
8, 40, 200 and 1000 mg/kg bw/day
Basis:
actual ingested
- No. of animals per sex per dose:
- Six
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: Based on results of a preliminary dose range-finding study conducted with 50, 250 and 1000 mg/kg bw/day.
- Post-exposure recovery period in satellite groups: 14 days recovery period with no dosing with test substance.
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: At least once per day.
DETAILED CLINICAL OBSERVATIONS: No data.
BODY WEIGHT: Yes.
- Time schedule for examinations: Two days before dosing started, Day 1 of dosing, then Days 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26 and 28. During the recovery period animals were weighed on Recovery Day 1, 3, 5, 8, 10, 12 and 14.
FOOD CONSUMPTION: Measured once before dosing, then twice per week (no further details).
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No.
WATER CONSUMPTION: No.
OPHTHALMOSCOPIC EXAMINATION: No.
HAEMATOLOGY: Yes
- Time schedule for collection of blood: At the end of the dosing and recovery periods.
- Anaesthetic used for blood collection: Yes (ether).
- Animals fasted: Yes, overnight.
- How many animals: All animals.
- Parameters checked in table No.1 were examined.
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: At the end of the dosing and recovery periods.
- Animals fasted: Yes, overnight.
- How many animals: All animals.
- Parameters checked in table No.1 were examined.
URINALYSIS: Yes
- Time schedule for collection of urine: 16-hour urine samples collected at the end of the dosing and recovery periods.
- Metabolism cages used for collection of urine: Yes
- Animals fasted: Yes, overnight.
- Parameters checked in table No.1 were examined.
NEUROBEHAVIOURAL EXAMINATION: No - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes (see table 2)
HISTOPATHOLOGY: Yes (see table 2) - Statistics:
- Data regarding body weights, food consumption, haematological examination, blood chemistry, urine volume and organ weights were analysed using Bartlett's test for homogeneity of variance. If the variances were homogeneous at a significance level of 5%, one way analysis of variance was performed. When there was a significant difference in this analysis, the difference between the vehicle control group and each of the treatment group analysed by Dunnett's test. If the variances were not homogeneous in the Bartlett's test, Kruskal-Wallis's test was used. When there was a significance in this test, the difference between the control group and each of the treatment groups was analysed by nonparametric Dunnett's test.
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- not examined
- Details on results:
- CLINICAL SIGNS AND MORTALITY: There were no deaths. During the dosing period, unkempt hair was observed in males of the 1000 mg/kg bw/day group. Although salivation was observed in all groups including the vehicle control group and frequency of this sign was different between the vehicle control group and the 1000 mg/kg bw/day group, it was not considered to be an adverse toxicological effect because the sign was observed just after dosing and it had no related other findings.
BODY WEIGHT AND WEIGHT GAIN: There was no adverse effect on body weights of any group.
FOOD CONSUMPTION: No adverse effects.
HAEMATOLOGY: At the end of the dosing period there were no differences between treated and control animals. At the end of the recovery period the highest dose group had a decrease in mean corpuscular volume.
CLINICAL CHEMISTRY: At the end of the dosing period, an increase in serum calcium level and a decrease in serum chloride level were observed in males of the 1000 mg/kg bw/day group. Increases in serum GPT, gamma-GTP activities, total cholesterol, total protein levels and decreases in serum cholinesterase activity and A/G ratio were observed in females of the 1000 mg/kg bw/day groups. A decrease in serum GOT activity was observed in males of all treated animals. These changes were concluded to be non-adverse.
URINALYSIS: No adverse effects.
ORGAN WEIGHTS: At the end of the dosing period, an increase in relative liver weight was observed in both sexes of the groups dosed with 200 mg/kg bw/day and over. Increases in absolute liver weight were observed in both sexes of the 1000 mg/kg bw/day group. An increase in relative kidney weight was observed in males of the 1000 mg/kg bw/day group. At the end of the recovery period there was a increase in relative kidney weights in males of the 1000 mg/kg bw/day group.
GROSS PATHOLOGY: Enlargement of the liver was observed in both sexes of the 1000 mg/kg bw/day group at the end of the dosing period. There was no such finding at the end of the recovery period.
HISTOPATHOLOGY: NON-NEOPLASTIC: In histopathological examination at the terminal autopsy of the dosing period, swelling of the hepatocytes in the liver was observed in both sexes of the 1000 mg/kg bw/day group. Increased eosinophilic bodies of the kidney was observed in males of the 1000 mg/kg bw/day group.
Effect levels
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- >= 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: No adverse effects observed at any dose level.
Target system / organ toxicity
- Critical effects observed:
- no
Applicant's summary and conclusion
- Conclusions:
- In a 28-day oral gavage study (Hita Research Laboratories, 1998) conducted to OECD Test Guideline 407 and in compliance with GLP, the NOAEL was at least 1000 mg/kg bw/day as no adverse effects were observed.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)
Sebbene gran parte del materiale online fornito dall'ECHA sia accessibile nella tua lingua, alcuni contenuti di questa pagina sono disponibili solo in inglese. Maggiori informazioni sulla prassi dell'ECHA in materia di multilinguismo.
Benvenuti al sito dell'ECHA. Non tutte le funzionalità del presente sito sono fruibili con Internet Explorer 7 (e versioni precedenti). Aggiornare Internet Explorer a una versione più recente.
Questo sito web si avvale di cookie affinché possiate usufruire della migliore esperienza sui nostri siti web.
Per saperne di più su come utilizziamo i cookie.